- Company also names Theodore Reiss EVP and Chief Medical Officer, and Jorg Thommes EVP, Pharmaceutical Sciences and OperationsCAMBRIDGE, Mass. (BUSINESS WIRE) Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, in.
Published: Jun 03, 2021 By Alex Keown
180 Life Sciences Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Officer. Her most recent role was at Columbia University as Managing Director of NY Life Science Venture Fund.